Welcome to our dedicated page for Inari Medical news (Ticker: $NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inari Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inari Medical's position in the market.
Inari Medical, Inc. will be participating in the 2024 Bank of America Securities Healthcare Conference to present their medical device solutions for venous and other diseases. The presentation will take place on May 15, 2024, at 11:20 AM Pacific Time, with a live webcast available on their website for 30 days.
Inari Medical, Inc. reported a strong first quarter with revenue of $143.2 million, up 23.3% year-over-year. Despite a GAAP operating loss of $17.2 million, non-GAAP operating loss improved to $5.6 million. The company continues to focus on growth, driving adoption of its toolkits and investing in clinical data. Gross margin was 86.8%, and operating expenses increased due to personnel-related expenses. Inari expects full-year 2024 revenue of $592.5-602.5 million and aims for sustained operating profitability in the first half of 2025.
